Loading…
Tenascin Expression and Angiogenesis in Breast Cancers
The expression and the distribution of tenascin as well as the extent of blood vessel formation (angiogenesis) were investigated in 70 invasive human breast carcinomas. Formalin-fixed, paraffin-embedded specimens were stained with monoclonal antibody against tenascin-C (DAKO and Biogenex). Anti-CD31...
Saved in:
Published in: | Pathology, research and practice research and practice, 1999-01, Vol.195 (12), p.821-828 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c322t-e7ca205987c9970f1c0b77b3d702933c72dce22835730811dbbc5113adfa63f03 |
---|---|
cites | cdi_FETCH-LOGICAL-c322t-e7ca205987c9970f1c0b77b3d702933c72dce22835730811dbbc5113adfa63f03 |
container_end_page | 828 |
container_issue | 12 |
container_start_page | 821 |
container_title | Pathology, research and practice |
container_volume | 195 |
creator | Tökés, Anna-Mária Hortoványi, Eszter Kulka, Janina Jäkel, Márta Kerényi, Tibor Kádár, Anna |
description | The expression and the distribution of tenascin as well as the extent of blood vessel formation (angiogenesis) were investigated in 70 invasive human breast carcinomas.
Formalin-fixed, paraffin-embedded specimens were stained with monoclonal antibody against tenascin-C (DAKO and Biogenex). Anti-CD31 antibody (Biogenex), an acknowledged marker of stromal angiogenesis, was used to detect endothelial cells.
Tenascin immunostaining was positive in the tumours around the persisting normal ducts, around tumour-cell nests, in the neostroma, in some tumour cells, and it was found in or around vascular channels.
Tumour vascularity was assessed by quantitative vascular grading (Chalkley point count) and was related to the localization and intensity of tenascin immunoreactivity.
19 tumours (27.1%) were scored as low, 35 (50%) as medium, and 16 (22.9%) as having a high vascular grade. The positive correlation between the vascular grade and the tenascin immunopositivity in tumour stroma was observed.
Our results suggest that tenascin expression may be associated with endothelial cell activation and may play an important role in tumour angiogenesis. |
doi_str_mv | 10.1016/S0344-0338(99)80104-6 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69403090</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0344033899801046</els_id><sourcerecordid>69403090</sourcerecordid><originalsourceid>FETCH-LOGICAL-c322t-e7ca205987c9970f1c0b77b3d702933c72dce22835730811dbbc5113adfa63f03</originalsourceid><addsrcrecordid>eNqFkD1PwzAQhi0EoqXwE0CZEAyBc5zY8YRKVT6kSgyU2XLsS2XUOsVuEfx7kqZCbEw33PPeq3sIOadwQ4Hy21dgeZ4CY-WVlNclUMhTfkCGlNMyBc7oIRn-IgNyEuM7AAjI6TEZ0A4QVAwJn6PX0TifTL_WAWN0jU-0t8nYL1yzQI_RxaRd3wfUcZNMtDcY4ik5qvUy4tl-jsjbw3Q-eUpnL4_Pk_EsNSzLNikKozMoZCmMlAJqaqASomJWQCYZMyKzBrOsZIVgUFJqq8oUlDJta81ZDWxELvu769B8bDFu1MpFg8ul9thso-IyBwayA4seNKGJMWCt1sGtdPhWFFQnTO2Eqc6GklLthCne5i72BdtqhfZPqjfUAnc9gO2bnw6Dam1hK8G6gGajbOP-qfgBWDx46Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69403090</pqid></control><display><type>article</type><title>Tenascin Expression and Angiogenesis in Breast Cancers</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Tökés, Anna-Mária ; Hortoványi, Eszter ; Kulka, Janina ; Jäkel, Márta ; Kerényi, Tibor ; Kádár, Anna</creator><creatorcontrib>Tökés, Anna-Mária ; Hortoványi, Eszter ; Kulka, Janina ; Jäkel, Márta ; Kerényi, Tibor ; Kádár, Anna</creatorcontrib><description>The expression and the distribution of tenascin as well as the extent of blood vessel formation (angiogenesis) were investigated in 70 invasive human breast carcinomas.
Formalin-fixed, paraffin-embedded specimens were stained with monoclonal antibody against tenascin-C (DAKO and Biogenex). Anti-CD31 antibody (Biogenex), an acknowledged marker of stromal angiogenesis, was used to detect endothelial cells.
Tenascin immunostaining was positive in the tumours around the persisting normal ducts, around tumour-cell nests, in the neostroma, in some tumour cells, and it was found in or around vascular channels.
Tumour vascularity was assessed by quantitative vascular grading (Chalkley point count) and was related to the localization and intensity of tenascin immunoreactivity.
19 tumours (27.1%) were scored as low, 35 (50%) as medium, and 16 (22.9%) as having a high vascular grade. The positive correlation between the vascular grade and the tenascin immunopositivity in tumour stroma was observed.
Our results suggest that tenascin expression may be associated with endothelial cell activation and may play an important role in tumour angiogenesis.</description><identifier>ISSN: 0344-0338</identifier><identifier>EISSN: 1618-0631</identifier><identifier>DOI: 10.1016/S0344-0338(99)80104-6</identifier><identifier>PMID: 10631717</identifier><language>eng</language><publisher>Germany: Elsevier GmbH</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Angiogenesis ; Breast cancer ; Breast Neoplasms - blood supply ; Breast Neoplasms - metabolism ; Breast Neoplasms - pathology ; Carcinoma, Ductal, Breast - blood supply ; Carcinoma, Ductal, Breast - metabolism ; Carcinoma, Ductal, Breast - pathology ; Female ; Humans ; Immunoenzyme Techniques ; Ki-67 Antigen - metabolism ; Middle Aged ; Neoplasm Staging ; Neovascularization, Pathologic - metabolism ; Neovascularization, Pathologic - pathology ; Prognosis ; Receptors, Estrogen - metabolism ; Tenascin ; Tenascin - metabolism ; Tumor Suppressor Protein p53 - metabolism</subject><ispartof>Pathology, research and practice, 1999-01, Vol.195 (12), p.821-828</ispartof><rights>1999 Urban & Fischer Verlag</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c322t-e7ca205987c9970f1c0b77b3d702933c72dce22835730811dbbc5113adfa63f03</citedby><cites>FETCH-LOGICAL-c322t-e7ca205987c9970f1c0b77b3d702933c72dce22835730811dbbc5113adfa63f03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10631717$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tökés, Anna-Mária</creatorcontrib><creatorcontrib>Hortoványi, Eszter</creatorcontrib><creatorcontrib>Kulka, Janina</creatorcontrib><creatorcontrib>Jäkel, Márta</creatorcontrib><creatorcontrib>Kerényi, Tibor</creatorcontrib><creatorcontrib>Kádár, Anna</creatorcontrib><title>Tenascin Expression and Angiogenesis in Breast Cancers</title><title>Pathology, research and practice</title><addtitle>Pathol Res Pract</addtitle><description>The expression and the distribution of tenascin as well as the extent of blood vessel formation (angiogenesis) were investigated in 70 invasive human breast carcinomas.
Formalin-fixed, paraffin-embedded specimens were stained with monoclonal antibody against tenascin-C (DAKO and Biogenex). Anti-CD31 antibody (Biogenex), an acknowledged marker of stromal angiogenesis, was used to detect endothelial cells.
Tenascin immunostaining was positive in the tumours around the persisting normal ducts, around tumour-cell nests, in the neostroma, in some tumour cells, and it was found in or around vascular channels.
Tumour vascularity was assessed by quantitative vascular grading (Chalkley point count) and was related to the localization and intensity of tenascin immunoreactivity.
19 tumours (27.1%) were scored as low, 35 (50%) as medium, and 16 (22.9%) as having a high vascular grade. The positive correlation between the vascular grade and the tenascin immunopositivity in tumour stroma was observed.
Our results suggest that tenascin expression may be associated with endothelial cell activation and may play an important role in tumour angiogenesis.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angiogenesis</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - blood supply</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - pathology</subject><subject>Carcinoma, Ductal, Breast - blood supply</subject><subject>Carcinoma, Ductal, Breast - metabolism</subject><subject>Carcinoma, Ductal, Breast - pathology</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Ki-67 Antigen - metabolism</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Neovascularization, Pathologic - metabolism</subject><subject>Neovascularization, Pathologic - pathology</subject><subject>Prognosis</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Tenascin</subject><subject>Tenascin - metabolism</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><issn>0344-0338</issn><issn>1618-0631</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><recordid>eNqFkD1PwzAQhi0EoqXwE0CZEAyBc5zY8YRKVT6kSgyU2XLsS2XUOsVuEfx7kqZCbEw33PPeq3sIOadwQ4Hy21dgeZ4CY-WVlNclUMhTfkCGlNMyBc7oIRn-IgNyEuM7AAjI6TEZ0A4QVAwJn6PX0TifTL_WAWN0jU-0t8nYL1yzQI_RxaRd3wfUcZNMtDcY4ik5qvUy4tl-jsjbw3Q-eUpnL4_Pk_EsNSzLNikKozMoZCmMlAJqaqASomJWQCYZMyKzBrOsZIVgUFJqq8oUlDJta81ZDWxELvu769B8bDFu1MpFg8ul9thso-IyBwayA4seNKGJMWCt1sGtdPhWFFQnTO2Eqc6GklLthCne5i72BdtqhfZPqjfUAnc9gO2bnw6Dam1hK8G6gGajbOP-qfgBWDx46Q</recordid><startdate>19990101</startdate><enddate>19990101</enddate><creator>Tökés, Anna-Mária</creator><creator>Hortoványi, Eszter</creator><creator>Kulka, Janina</creator><creator>Jäkel, Márta</creator><creator>Kerényi, Tibor</creator><creator>Kádár, Anna</creator><general>Elsevier GmbH</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19990101</creationdate><title>Tenascin Expression and Angiogenesis in Breast Cancers</title><author>Tökés, Anna-Mária ; Hortoványi, Eszter ; Kulka, Janina ; Jäkel, Márta ; Kerényi, Tibor ; Kádár, Anna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c322t-e7ca205987c9970f1c0b77b3d702933c72dce22835730811dbbc5113adfa63f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angiogenesis</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - blood supply</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - pathology</topic><topic>Carcinoma, Ductal, Breast - blood supply</topic><topic>Carcinoma, Ductal, Breast - metabolism</topic><topic>Carcinoma, Ductal, Breast - pathology</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Ki-67 Antigen - metabolism</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Neovascularization, Pathologic - metabolism</topic><topic>Neovascularization, Pathologic - pathology</topic><topic>Prognosis</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Tenascin</topic><topic>Tenascin - metabolism</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tökés, Anna-Mária</creatorcontrib><creatorcontrib>Hortoványi, Eszter</creatorcontrib><creatorcontrib>Kulka, Janina</creatorcontrib><creatorcontrib>Jäkel, Márta</creatorcontrib><creatorcontrib>Kerényi, Tibor</creatorcontrib><creatorcontrib>Kádár, Anna</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pathology, research and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tökés, Anna-Mária</au><au>Hortoványi, Eszter</au><au>Kulka, Janina</au><au>Jäkel, Márta</au><au>Kerényi, Tibor</au><au>Kádár, Anna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tenascin Expression and Angiogenesis in Breast Cancers</atitle><jtitle>Pathology, research and practice</jtitle><addtitle>Pathol Res Pract</addtitle><date>1999-01-01</date><risdate>1999</risdate><volume>195</volume><issue>12</issue><spage>821</spage><epage>828</epage><pages>821-828</pages><issn>0344-0338</issn><eissn>1618-0631</eissn><abstract>The expression and the distribution of tenascin as well as the extent of blood vessel formation (angiogenesis) were investigated in 70 invasive human breast carcinomas.
Formalin-fixed, paraffin-embedded specimens were stained with monoclonal antibody against tenascin-C (DAKO and Biogenex). Anti-CD31 antibody (Biogenex), an acknowledged marker of stromal angiogenesis, was used to detect endothelial cells.
Tenascin immunostaining was positive in the tumours around the persisting normal ducts, around tumour-cell nests, in the neostroma, in some tumour cells, and it was found in or around vascular channels.
Tumour vascularity was assessed by quantitative vascular grading (Chalkley point count) and was related to the localization and intensity of tenascin immunoreactivity.
19 tumours (27.1%) were scored as low, 35 (50%) as medium, and 16 (22.9%) as having a high vascular grade. The positive correlation between the vascular grade and the tenascin immunopositivity in tumour stroma was observed.
Our results suggest that tenascin expression may be associated with endothelial cell activation and may play an important role in tumour angiogenesis.</abstract><cop>Germany</cop><pub>Elsevier GmbH</pub><pmid>10631717</pmid><doi>10.1016/S0344-0338(99)80104-6</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0344-0338 |
ispartof | Pathology, research and practice, 1999-01, Vol.195 (12), p.821-828 |
issn | 0344-0338 1618-0631 |
language | eng |
recordid | cdi_proquest_miscellaneous_69403090 |
source | ScienceDirect Freedom Collection 2022-2024 |
subjects | Adult Aged Aged, 80 and over Angiogenesis Breast cancer Breast Neoplasms - blood supply Breast Neoplasms - metabolism Breast Neoplasms - pathology Carcinoma, Ductal, Breast - blood supply Carcinoma, Ductal, Breast - metabolism Carcinoma, Ductal, Breast - pathology Female Humans Immunoenzyme Techniques Ki-67 Antigen - metabolism Middle Aged Neoplasm Staging Neovascularization, Pathologic - metabolism Neovascularization, Pathologic - pathology Prognosis Receptors, Estrogen - metabolism Tenascin Tenascin - metabolism Tumor Suppressor Protein p53 - metabolism |
title | Tenascin Expression and Angiogenesis in Breast Cancers |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T21%3A38%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tenascin%20Expression%20and%20Angiogenesis%20in%20Breast%20Cancers&rft.jtitle=Pathology,%20research%20and%20practice&rft.au=T%C3%B6k%C3%A9s,%20Anna-M%C3%A1ria&rft.date=1999-01-01&rft.volume=195&rft.issue=12&rft.spage=821&rft.epage=828&rft.pages=821-828&rft.issn=0344-0338&rft.eissn=1618-0631&rft_id=info:doi/10.1016/S0344-0338(99)80104-6&rft_dat=%3Cproquest_cross%3E69403090%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c322t-e7ca205987c9970f1c0b77b3d702933c72dce22835730811dbbc5113adfa63f03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=69403090&rft_id=info:pmid/10631717&rfr_iscdi=true |